德国放射肿瘤科医生对前列腺癌PET引导放疗的调查
该调查通过在线问卷发给德国放射肿瘤学会(DEGRO)成员,评估PET(尤其PSMA靶向示踪剂)在前列腺癌放疗中的接受度与使用模式。109名参与者中78.9%可在放疗计划中使用PET,98.8%的中心使用PSMA靶向示踪剂,但对生化复发后启动PET的PSA阈值及靶区剂量处方存在差异。
要点
- 78.9%的参与者可在放疗计划中使用PET,98.8%的中心使用PSMA靶向示踪剂。
- 生化复发后启动PSMA-PET的PSA阈值不一:39.5%在≥0.5 ng/mL,30.2%在≥0.2 ng/mL。
- PET阳性局部复发和盆腔淋巴结的中位总剂量(EQD2(1.5 Gy))分别为70.00 Gy和62.00 Gy。
核心结论
- PSMA-PET在德国放射肿瘤科医生中广泛使用,但其对治疗计划的具体影响因医生而异,需要进一步试验和指南。
研究设计与样本
- 在线问卷调查,通过电子邮件分发给德国放射肿瘤学会(DEGRO)成员,共109名参与者。
- 调查内容包括前列腺癌放疗伴/不伴PET的治疗模式,剂量评估采用α/β=1.5 Gy的2 Gy分次等效剂量[EQD2(1.5 Gy)]。
主要发现
- 109名参与者中,78.9%可在放疗计划中使用PET,大多数中心使用PSMA靶向示踪剂(98.8%)。
- 生化复发后启动PSMA-PET的PSA阈值分布:39.5%在≥0.5 ng/mL,30.2%在≥0.2 ng/mL,16.3%在≥1.0 ng/mL,2.3%在≥2.0 ng/mL,11.7%不论PSA。
- PET阳性局部复发和盆腔淋巴结时,分别有97.7%和96.5%的参与者会应用 escalated dose(剂量提升)。
- 局部复发的中位总剂量EQD2(1.5 Gy)为70.00 Gy(范围56.89-85.71),盆腔淋巴结为62.00 Gy(范围52.61-80.00)。
- 定义寡转移性前列腺癌时,最常描述的可适用远处病灶总数为≤3个(22.0%)或≤5个(20.2%)。
关键数值与推荐
- 生化复发后启动PSMA-PET的PSA阈值:≥0.5 ng/mL占39.5%,≥0.2 ng/mL占30.2%,≥1.0 ng/mL占16.3%,≥2.0 ng/mL占2.3%,不论PSA占11.7%。
- PET阳性局部复发的中位总剂量EQD2(1.5 Gy)为70.00 Gy(范围56.89-85.71)。
- PET阳性盆腔淋巴结的中位总剂量EQD2(1.5 Gy)为62.00 Gy(范围52.61-80.00)。
- 定义寡转移性前列腺癌的远处病灶总数:≤3个占22.0%,≤5个占20.2%。
临床怎么用
- PSMA-PET广泛用于前列腺癌放疗计划,但启动PET的PSA阈值和靶区剂量处方在不同医生间存在差异。
- 对PET阳性的局部复发和盆腔淋巴结,大多数医生会应用 escalated dose(剂量提升)。
局限性
- 调查基于德国放射肿瘤学会成员的自愿在线问卷,可能存在选择偏倚和应答偏倚。
- 样本量为109名参与者,结果可能不能完全代表所有放射肿瘤科医生的实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positron emission tomography-(PET) has evolved as a powerful tool to guide treatment for prostate cancer (PC). The aim of this survey was to evaluate the acceptance and use of PET-especially with prostate-specific membrane antigen (PSMA) targeting tracers-in clinical routine for radiotherapy (RT) and the impact on target volume definition and dose prescription. METHODS: We developed an online survey, which we distributed via e-mail to members of the German Society of Radiation Oncology (DEGRO). The survey included questions on patterns of care of RT for PC with/without PET. For evaluation of doses we used the equivalent dose at fractionation of 2 Gy with α/β = 1.5 Gy [EQD2(1.5 Gy)]. RESULTS: From 109 participants, 78.9% have the possibility to use PET for RT planning. Most centers use PSMA-targeting tracers (98.8%). In 39.5%, PSMA-PET for biochemical relapse after prior surgery is initiated at PSA ≥ 0.5 ng/mL, while 30.2% will perform PET at ≥ 0.2 ng/mL (≥ 1.0 ng/mL: 16.3%, ≥ 2.0 ng/mL: 2.3%, regardless of PSA: 11.7%). In case of PET-positive local recurrence (LR) and pelvic lymph nodes (LNs), 97.7% and 96.5% of the participants will apply an escalated dose. The median total dose in EQD2(1.5 Gy) was 70.00 Gy (range: 56.89-85.71) for LR and 62.00 Gy (range: 52.61-80.00) for LNs. A total number of ≤ 3 (22.0%) or ≤ 5 (20.2%) distant lesions was most often described as applicable for the definition as oligometastatic PC. CONCLUSION: PSMA-PET is widely used among German radiation oncologists. However, specific implications on treatment planning differ among physicians. Therefore, further trials and guidelines for PET-based RT are warranted.
引用
- Vogel MME, Dewes S, Sage EK, et al. A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. Radiat Oncol. 2021. PMID: 33933111. doi:10.1186/s13014-021-01811-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。